Press Releases Items Per Page 102550 News Category FinancialGeneral Year None2024202320222021202020192018201720162015201420132012201120102009200820072006 MOVENTIG® Approved In The European Union For Opioid-Induced Constipation Dec 09, 2014 Baxter Submits Application For US FDA Approval Of BAX 855, Extended Half-Life Recombinant FVIII Based On ADVATE For Hemophilia A Dec 01, 2014 Nektar Presents Preclinical Study Findings for Etirinotecan Pegol (NKTR-102) in Combination with a PARP Inhibitor in BRCA1-deficient Cancer Model Nov 20, 2014 Nektar Therapeutics Reports Financial Results for the Third Quarter of 2014 Nov 06, 2014 Nektar to Announce Financial Results for the Third Quarter 2014 on Thursday, November 6, 2014, After Close of U.S.-Based Financial Markets Oct 30, 2014 Nektar Therapeutics Announces MOVENTIG® (naloxegol) Receives Positive CHMP Opinion In EU For Treatment Of Adults With Opioid-Induced Constipation Sep 26, 2014 Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting Sep 19, 2014 FDA approves MOVANTIK™ (naloxegol) Tablets C-II for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain Sep 16, 2014 Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients Aug 21, 2014 Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 Jul 31, 2014 Pagination First page « first Previous page ‹ previous … Page 23 Page 24 Page 25 Page 26 Current page 27 Page 28 Page 29 Page 30 Page 31 … Next page next › Last page last »